The purpose of this study was to test metabolic modulation as a potential strategy to overcome imatinib resistance based on the possible crosstalk between BCR-ABL signaling and metabolic changes in CML. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.